Pfizer announces EC approves Abrysvo for immunization of pregnant individuals

Pfizer announced that the European Commission has granted marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus prefusion F vaccine, to help protect both infants through maternal immunization and older adults. Abrysvo is indicated for: Passive protection against lower respiratory tract disease caused by RSV in infants from birth through six months of age following maternal immunization during pregnancy and active immunization of individuals 60 years of age and older for the prevention of LRTD caused by RSV. “The approval of ABRYSVO in Europe marks significant progress in the scientific community’s efforts to provide meaningful protection against RSV, a common respiratory virus that could potentially be severe and even life-threatening, especially for infants and older adults. Last year’s significant number of newborns, children, and adults being hospitalized across Europe demonstrated the immense need for protection against severe RSV cases. The approval of the vaccine for both older adults and infants through maternal immunization is a triumph for public health and we hope to see a tremendous impact for future seasons,” said Annaliesa Anderson, Ph.D., Senior Vice President and Head Vaccine Research and Development, Pfizer.